IPA MindWalk Holdings Corp.


$ 1.88 $ 0.26 (16.15 %)    

Friday, 31-Oct-2025 19:00:31 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.87
$ 1.63
$ 1.62 x 1
$ 1.86 x 100
$ 1.62 - $ 1.93
$ 0.27 - $ 3.25
1,129,981
na
na
$ 1.19
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunoprecise-rebrands-as-mindwalk-unifies-subsidiaries-and-changes-ticker-to-hyft

An Evolution in Name, Structure, and Strategy Reflecting the Company's AI-Driven Platform and Bio-Native Discovery Vision

 immunoprecise-antibodies-announces-results-of-a-newly-expanded-study-demonstrating-that-its-lensai-immunogenicity-screening-can-reliably-predict-anti-drug-antibody-risk-for-therapeutic-proteins-before-they-enter-animal-studies-or-human-trials

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where Te...

 immunoprecises-lensai-achieves-ability-to-accurately-predict-binding-on-17-previously-unseen-antibody-antigen-complexes-achieving-near-crystallography-precision-without-prior-training-data

New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, a...

 immunoprecise-confirms-ai-discovered-dengue-vaccine-target-is-safe-and-triggers-immune-response

ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, pr...

 immunoprecises-ai-powered-lensai-platform-driven-by-patented-hyft-technology-identifies-a-highly-conserved-multi-factorial-epitope-across-all-four-dengue-virus-serotypes

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.ImmunoPrec...

 immunoprecise-announces-benchmarking-results-for-lensai-epitope-mapping

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchm...

 hc-wainwright--co-reiterates-buy-on-immunoprecise-antibodies-maintains-5-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Buy and maint...

 immunoprecise-antibodies-announces-its-support-for-fdas-recent-decision-to-phase-out-animal-testing-requirements-for-monoclonal-antibodies-and-other-pharmaceutical-products

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced its strong support for ...

 benchmark-reiterates-speculative-buy-on-immunoprecise-antibodies-maintains-3-price-target

Benchmark analyst Robert Wasserman reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and maintains $3 ...

 hc-wainwright--co-maintains-buy-on-immunoprecise-antibodies-lowers-price-target-to-5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Buy and lowers...

 immunoprecise-antibodies-q3-2025-gaap-eps-c066-may-not-be-comparable-to-c008-estimate-sales-c615m-miss-c658m-estimate

ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION